ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_1001494

psoriasis vulgaris

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. psoriasis vulgaris. Diseases, record EFO_1001494. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001494

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
psoriasis vulgaris
Open Targets ID
EFO_1001494
Other names
plaque psoriasis
Highest stage of its drugs
Approval, for 34 of its 167 drugs, from DailyMed, PMDA and TTD

Source Open Targets

Drugs167

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
CALCIPOTRIENECHEMBL1200666Small moleculeApprovalDailyMed, PMDA and TTD655554Drugs and targets
BETAMETHASONE DIPROPIONATECHEMBL1200384Small moleculeApprovalDailyMed443534Drugs and targets
APREMILASTCHEMBL514800Small moleculeApprovalPMDA and TTD353333Drugs and targets
ETANERCEPTCHEMBL1201572ProteinApprovalDailyMed312828Drugs and targets
ADALIMUMABCHEMBL1201580AntibodyApprovalPMDA372626Drugs and targets
SECUKINUMABCHEMBL1743068AntibodyApprovalDailyMed, PMDA and TTD282525Drugs and targets
USTEKINUMABCHEMBL1201835AntibodyApprovalDailyMed, PMDA and TTD292222Drugs and targets
DEUCRAVACITINIBCHEMBL4435170Small moleculeApprovalPMDA and TTD252222Drugs and targets
RISANKIZUMABCHEMBL3990029AntibodyApprovalPMDA and TTD211919Drugs and targets
EFALIZUMABCHEMBL1201575AntibodyApprovalTTD181717Drugs and targets

1 to 10 of 167

See all 167 drugs

Targets165

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor9Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
IL12BInterleukin-127Interleukin-12 inhibitor; Interleukin-23 inhibitorApprovalhttps://conductscience.org/library/genes/3593Drugs and targets
IL23AInterleukin-237Interleukin-23 inhibitorApprovalhttps://conductscience.org/library/genes/51561Drugs and targets
JAK1Janus Kinase (JAK)7Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitorPhase 3https://conductscience.org/library/genes/3716Drugs and targets
IL17AInterleukin-17A6Interleukin 17A binding agent; Interleukin 17A inhibitorApprovalhttps://conductscience.org/library/genes/3605Drugs and targets
JAK2Janus Kinase (JAK)6Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitorPhase 3https://conductscience.org/library/genes/3717Drugs and targets
TNFTumor necrosis factor6TNF-alpha inhibitorApprovalhttps://conductscience.org/library/genes/7124Drugs and targets
TYK2Janus Kinase (JAK)6Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulatorApprovalhttps://conductscience.org/library/genes/7297Drugs and targets
VDRVitamin D3 receptor5Vitamin D receptor agonistApprovalhttps://conductscience.org/library/genes/7421Drugs and targets
JAK3Janus Kinase (JAK)4Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitorPhase 3https://conductscience.org/library/genes/3718Drugs and targets

1 to 10 of 165

See all 165 targets

Trials467

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 23 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00322439Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis2,5112014-03-26PsoriasisETANERCEPTIts record names the diseaseClinicalTrials.gov
NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )Phase 32,1702024-12-11PsoriasisRISANKIZUMABIts record names the diseaseClinicalTrials.gov
NCT03556202A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)Phase 31,9362023-03-21PsoriasisMIRIKIZUMABIts record names the diseaseClinicalTrials.gov
NCT01708603P3 Study Brodalumab in Treatment of Moderate to Severe Plaque PsoriasisPhase 31,8312020-01-06Moderate to Severe Plaque PsoriasisBRODALUMAB, USTEKINUMABIts record names the diseaseClinicalTrials.gov
NCT02486302
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
1,5342019-06-24Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque PsoriasisETANERCEPTIts record names the diseaseClinicalTrials.gov
NCT03535194A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)Phase 31,4842021-03-30PsoriasisMIRIKIZUMABIts record names the diseaseClinicalTrials.gov
NCT03598790A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisPhase 31,3532024-12-06Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque PsoriasisBIMEKIZUMABIts record names the diseaseClinicalTrials.gov
NCT01646177A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)Phase 31,3462016-10-21PsoriasisETANERCEPT, IXEKIZUMABIts record names the diseaseClinicalTrials.gov
NCT01474512A Phase 3 Study in Participants With Moderate to Severe PsoriasisPhase 31,2962016-05-27PsoriasisIXEKIZUMABIts record names the diseaseClinicalTrials.gov
NCT00249808A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic TherapiesPhase 41,2662018-03-20PsoriasisEFALIZUMABIts record names the diseaseClinicalTrials.gov

1 to 10 of 467

See all 467 trials

Comparisons in its trials171

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
BMS-986165 vs Placebo: The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)
271 of 51124 of 255766NCT03611751Trial comparisons
BMS-986165 vs Placebo: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)253 of 51122 of 255766NCT03611751Trial comparisons
BMS-986165 vs Apremilast: The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)
271 of 511101 of 254765NCT03611751Trial comparisons
BMS-986165 vs Apremilast: The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)253 of 51186 of 254765NCT03611751Trial comparisons
BMS-986165 vs Apremilast: The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)251 of 50475 of 254758NCT03611751Trial comparisons
BMS-986165 vs Apremilast: The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)
296 of 50496 of 254758NCT03611751Trial comparisons
BMS-986165 vs Apremilast: The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)
164 of 50450 of 254758NCT03611751Trial comparisons
BMS-986165 vs Placebo: The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)186 of 49524 of 246741NCT03611751Trial comparisons
AIN457 300 mg vs Ustekinumab: serious adverse events41 of 33532 of 336671NCT02074982Trial comparisons
LEO 90100 vs Daivobet Ointment: deaths from any cause0 of 3000 of 301601NCT05919082Trial comparisons

1 to 10 of 171

See all 171 comparisons in its trials

Papers from its trials275

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
41850772RESULT1PubMed
41800601RESULT3PubMed
41678327RESULT1PubMed
41580158RESULT4PubMed
41359217RESULT3PubMed
41060492RESULT3PubMed
40788331RESULT1PubMed
40156698RESULT1PubMed
39578348RESULT3PubMed
39328126RESULT1PubMed

1 to 10 of 275

See all 275 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001494

GET https://conductscience.org/api/diseases/v1/EFO_1001494/drugs?page=2

API referenceFor AI assistants